jackie.vuistiner

Tribune de Côte d’Azur: CUTISS Innovation wins Impact Award 2022

The Tribune de Côte d’Azur covered the first ‘Impact Awards’ 2022, a jury-led competition organized by Team Côte d’Azur that recognizes leading companies of the local economic ecosystem. CUTISS Innovation, our French subsidiary, was honored to win the ‘Innovation’ trophy for continued innovation and research into regenerative medicine and skin pigmentation. Our director Cécile Cousin was …

Tribune de Côte d’Azur: CUTISS Innovation wins Impact Award 2022 Read More »

Recruitment completed for denovoSkin Phase 2 clinical trial, adult & adolescent patients

PRESS RELEASE CUTISS completes recruitment for denovoSkin™ Phase 2 clinical trial in adult and adolescent burn patients Switzerland, 7 September 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the completion of recruitment for the Phase 2 clinical trial of its lead product denovoSkin™ …

Recruitment completed for denovoSkin Phase 2 clinical trial, adult & adolescent patients Read More »

CUTISS granted European patent for skin tissue graft

CUTISS is pleased to announce that a tissue graft patent has been granted by the European Patent Office for the personalized bioengineered human skin tissue therapy developed by CUTISS. The patent (3174563) has been granted pursuant to Article 97(1) EPC to University of Zurich (UZH) where the founders of CUTISS worked at the time of …

CUTISS granted European patent for skin tissue graft Read More »

CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator

CUTISS achieves full independence in its manufacturing capabilities with onsite facility. Increased agility and capacity in producing denovoSkin for current and future clinical trials and patients on compassionate basis. Successful transfer of technology and departure from Wyss Zurich Translational Center, a joint accelerator created by Hansjörg Wyss together with the University of Zurich and ETH …

CUTISS starts onsite denovoSkin™ production and successfully exits Wyss Zurich accelerator Read More »

IBSA Pharma and CUTISS complete license agreement for VitiCell

PRESS RELEASE  Two innovative biotechnology specialists, IBSA Pharma and CUTISS complete license agreement for VitiCell® Agreement grants CUTISS exclusive worldwide license to commercialize VitiCell®. VitiCell® is a CE marked medical device developed by IBSA for the treatment of skin pigmentation disorders. Strategic fit with CUTISS’s expertise in skin tissue bioengineering. Sophia-Antipolis (France) and Zurich (Switzerland), 2 …

IBSA Pharma and CUTISS complete license agreement for VitiCell Read More »

CUTISS opens R&D subsidiary in France and secures first grant

CUTISS opens subsidiary in France and secures first government grant to extend its Research and Development in regenerative medicine The subsidiary CUTISS Innovation, based at Sophia Antipolis, Europe’s leading technology park, will focus on R&D and innovation in regenerative medicine. A grant of EUR 300,000 from the Region Provence-Alpes-Cote d’Azur will contribute towards the installation …

CUTISS opens R&D subsidiary in France and secures first grant Read More »

Swissmedic grants CUTISS certificates of Good Manufacturing and Distribution Practices

CUTISS’s first onsite manufacturing facility in Schlieren, Zurich, has received the certification of compliance for Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) from the regulator Swissmedic, the Swiss Agency for Therapeutic Products. The GMP and GDP certifications authorizes the collection, manufacturing, testing, storage, release, and distribution of Transplant Products (TpP), Gene Therapy (GT) …

Swissmedic grants CUTISS certificates of Good Manufacturing and Distribution Practices Read More »

Scroll to Top

Newsletter

Would you like to contact us as a journalist?

©WyssZurich

This website uses cookies to ensure you get the best experience on our website.